Advertisement

Targeted Oncology

, Volume 9, Issue 1, pp 63–71 | Cite as

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma

  • Laura M. AlwanEmail author
  • Kenneth Grossmann
  • Daniel Sageser
  • Joan Van Atta
  • Neeraj Agarwal
  • Jeffrey A. Gilreath
Original Research

Abstract

We compared acute toxicity, drug exposure, in-hospital mortality, and inpatient length of stay between two currently recommended dosing protocols (from the National Comprehensive Cancer Network Guidelines) of high-dose interleukin-2 (IL-2) treatment for patients with metastatic melanoma. Patients with metastatic melanoma who received high-dose IL-2 treatment between 2003 and 2010 were identified. Chemotherapy orders, electronic medical records, paper medical charts, and patient discharge summaries were reviewed retrospectively. We identified 13 patients who had received 600,000 units/kilogram (kg)/dose and 15 patients who had received 720,000 units/kg/dose. Patients in the 720,000 units/kg/dose group had a higher rate of grade 3 and 4 bilirubin elevations (34 vs. 12 %), weight gain (any grade, 96 vs. 89 %), and thrombocytopenia (any grade, 75 vs. 65 %). Patients receiving the higher dose also experienced more dose-limiting neurotoxicity (45 vs. 23 %), large-volume diarrhea (15 vs. 0 %), and hepatotoxicity (7 vs. 0 %). There was no in-hospital mortality during treatment in either group. The average length of stay was similar between both groups (5 days, SD = 1 for both groups), and the median cumulative IL-2 exposure was similar between both groups for the first course (10.1 vs.10.5 million units/kg) and for all courses (approximately 11–12 million units/kg). Both high-dose IL-2 protocols had comparable in-hospital mortality and cumulative IL-2 exposure. The 720,000 units/kg/dose dosing scheme did not shorten the length of stay but did lead to greater acute toxicity. Therefore, as a result, we recommend 600,000 units/kg/dose when deciding between the two regimens.

Keywords

High dose Interleukin-2 Metastatic Melanoma Toxicity 

Notes

Conflict of interest

This research was not funded by any organization and the authors have no conflicts to disclose in regards to funding of this research. Additional potential conflict of interest information has been completed and submitted by each author and is attached in this submission.

References

  1. 1.
    NCCN Clinical Practice Guidelines in Oncology (2013) Melanoma. Version 2.2013. http://nccn.org. Accessed 6 February
  2. 2.
    American Cancer Society (2013) Melanoma skin cancer. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/index. Accessed 6 February
  3. 3.
    DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Cutaneous melanoma. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951Google Scholar
  4. 4.
    Miller AJ, Mihm MC Jr (2006) Mechanisms of disease: melanoma. N Engl J Med 355:51–65PubMedCrossRefGoogle Scholar
  5. 5.
    Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116PubMedGoogle Scholar
  6. 6.
    Smith FO, Downey SG, Klapper JA et al (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14:5610–5618PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Eton O, Legha SS, Bedikian AY et al (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045–2052PubMedCrossRefGoogle Scholar
  10. 10.
    Bedikian AY, Johnson MM, Warneke CL et al (2008) Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5:201–207PubMedCrossRefGoogle Scholar
  11. 11.
    Atkins MB, Hsu J, Lee S et al (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748–5754PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166PubMedGoogle Scholar
  13. 13.
    Amaravadi RK, Flaherty KT (2007) Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol 5:386–393PubMedGoogle Scholar
  14. 14.
    Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488–496Google Scholar
  15. 15.
    Aldesleukin (Proleukin) package insert (2009) Novartis Pharmaceuticals Corporations, East Hanover, NJGoogle Scholar
  16. 16.
    DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Interleukin therapy. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951Google Scholar
  17. 17.
    DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2005) Interleukin-2. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott Williams and Wilkins, Philadelphia, pp 431–438Google Scholar
  18. 18.
    Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907–913PubMedCrossRefGoogle Scholar
  19. 19.
    Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS (2007) Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced disease progression after biochemotherapy. J Clin Oncol 25:3802–3807PubMedCrossRefGoogle Scholar
  20. 20.
    Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Cancer Therapy Evaluation Program (2010) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. August 9, 2006, http://ctep.cancer.gov. Accessed 15 March
  22. 22.
    Nafcillin. Drugdex®. Thomson Micromedex. Greenwood Village, CO. http://www.thomsonhc.com/hcs/librarian. Accessed 20 June 2010
  23. 23.
    Nezos A, Msaouel P, Pissimissis N et al (2011) Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 37:284–290PubMedCrossRefGoogle Scholar
  24. 24.
    Ireland A, Millward M, Pearce R, Lee M, Ziman M (2011) Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327–336PubMedCrossRefGoogle Scholar
  25. 25.
    Acquavella N, Kluger H, Rhee J et al (2008) Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 31:569–576PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  • Laura M. Alwan
    • 1
    Email author
  • Kenneth Grossmann
    • 2
  • Daniel Sageser
    • 3
  • Joan Van Atta
    • 4
  • Neeraj Agarwal
    • 2
  • Jeffrey A. Gilreath
    • 3
  1. 1.Department of Pharmacy ServicesUniversity of Washington Medical Center/Seattle Cancer Care AllianceSeattleUSA
  2. 2.Department of MedicineUniversity of Utah Hospitals and ClinicsSalt Lake CityUSA
  3. 3.Department of Pharmacy Services, Huntsman Cancer InstituteUniversity of Utah Hospitals and ClinicsSalt Lake CityUSA
  4. 4.Department of NursingHuntsman Cancer InstituteSalt Lake CityUSA

Personalised recommendations